Published in Haematologica on August 02, 2013
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | NCT00952289
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica (2015) 1.10
Imatinib and ruxolitinib association: first experience in two patients. Haematologica (2014) 0.91
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol (2016) 0.90
The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma (2012) 0.84
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia (2014) 0.81
Novel therapies for myelofibrosis. Leuk Lymphoma (2015) 0.79
Methotrexate Is a JAK/STAT Pathway Inhibitor. PLoS One (2015) 0.79
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med (2015) 0.76
Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors. J Adv Pract Oncol (2015) 0.75
Experience with ruxolitinib in the treatment of polycythaemia vera. Ther Adv Hematol (2017) 0.75
JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood (2017) 0.75
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev (2017) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol (2010) 1.90
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia (2008) 1.77
MPN-associated myelofibrosis (MPN-MF). Leuk Res (2010) 1.25
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol (2010) 1.10
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res (2013) 1.00
How to manage the transplant question in myelofibrosis. Blood Cancer J (2012) 0.89
Anagrelide and cardiovascular events. Much ado about nothing? Leuk Res (2011) 0.81
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 7.00
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 6.05
Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest (2005) 5.91
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg (2009) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol (2008) 4.53
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns (2002) 4.30
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem (2002) 4.19
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol (2010) 4.18
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med (2005) 4.10
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med (2006) 4.07